Abstract
Ambrisentan [Volibris® (EU), Letairis® (USA)] is an effective and well-tolerated first-line option for the treatment of adults with pulmonary arterial hypertension (PAH) classified as WHO functional class II or III. Ambrisentan provides sustained improvements in exercise capacity and dyspnoea, stabilizes WHO functional class, increases time to clinical worsening, and has an acceptable tolerability and safety profile. Ambrisentan is associated with fewer drug interactions than other available endothelin-1 receptor antagonists, may be used concomitantly with other common PAH medications, is associated with a low risk of liver function abnormalities, and has a convenient once-daily oral administration regimen.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
